Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Parkinsonism & Related Disorders

• Publication date

  2017-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.parkreldis.2016.12.030PMID 28063683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improvement of dyskinesias with l‐dopa infusion in advanced Parkinson's disease

  2016cited by this paper
• Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients

  2016cited by this paper
• Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: Management inclinical practice.

  2015cited by this paper
• Features and Mechanisms of Diphasic Dyskinesia in Parkinson’s Disease

  2014cited by this paper
• Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

  2014cited by this paper
• Complexity of Motor Response to Different Doses of Duodenal Levodopa Infusion in Parkinson Disease

  2012cited by this paper
• Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets

  2003cited by this paper
• The spectrum of levodopa-induced dyskinesias.

  2000cited by this paper
• Treating and Preventing Levodopa-Induced Dyskinesias

  1999cited by this paper
• Levodopa‐induced diphasic dyskinesias improved by subcutaneous apomorphine

  1992cited by this paper
• Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification

  1992cited by this paper
• Levodopa‐induced dyskinesia

  1990cited by this paper
• Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.

  1977cited by this paper
• L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

  1971cited by this paper

• A video-atlas of levodopa-induced dyskinesia in Parkinson’s disease: terminology matters

  2023cites this paper
• Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions

  2023cites this paper
• Is Disrupted Mitophagy a Central Player to Parkinson’s Disease Pathology?

  2023cites this paper
• Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up

  2022cites this paper
• Development of Quality of Life Questionnaire for Patients with Parkinson’s Disease Undergoing STN-DBS

  2021cites this paper
• Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review

  2021cites this paper
• [Optimal dose of levodopa-carbidopa intestinal gel in the treatment of diphasic dyskinesia and freezing of gait].

  2021cites this paper
• Current Knowledge on the Background, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesia – Literature Review.

  2021cites this paper
• Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson’s Disease

  2021cites this paper
• Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review

  2021cites this paper
• Parkinson ' s Disease with Device , Diary , or in Disguise . Dyskinesia reduction , motor state evaluation , and workforce participation among persons with Parkinson ' s disease

  2021cites this paper
• Levodopa/Carbidopa Intestinal Gel Long‐Term Outcome in Parkinson's Disease: Focus on Dyskinesia

  2020cites this paper
• Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies

  2020cites this paper
• Successful Treatment of Levodopa/Carbidopa Intestinal Gel Associated “Biphasic‐like” Dyskinesia with Pallidal Deep Brain Stimulation

  2020cites this paper
• Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.

  2019cites this paper
• Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update

  2019cites this paper
• Dyskinesia Matters

  2019cites this paper
• Levodopa-induced dyskinesia: clinical features, incidence, and risk factors

  2018cites this paper
• Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts

  2018cites this paper
• Levodopa in Parkinson’s Disease: Current Status and Future Developments

  2017cites this paper